Inhibition of poly(ADP-ribose) polymerase in cancer

Curr Opin Pharmacol. 2006 Aug;6(4):364-8. doi: 10.1016/j.coph.2006.02.004. Epub 2006 Jun 5.

Abstract

Inhibition of the DNA repair enzyme poly(ADP-ribose) polymerase-1 (PARP-1) has been extensively investigated in the pre-clinical setting as a strategy for chemo- or radio-potentiation. Recent evidence has suggested that PARP inhibitors might be active as single agents in certain rare inherited cancers that carry DNA repair defects. As a result, potent PARP-1 inhibitors have in the past three years entered early clinical trials in cancer patients, and the final results of these trials are eagerly awaited.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Neoplasms / radiotherapy
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Poly(ADP-ribose) Polymerases / metabolism

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases